Salisbury Foundation Trust

FOI_5658

Internal Reference Number: FOI_5658

Date Request Received: 11/05/2020 11:15:15

Date Request Replied To: 15/06/2020 13:20:23

This response was sent via: By Email

Request Summary: Breast Cancer FOI - Pathology Dept query

Request Category: Researcher






 
Question Number 1:
Respondent/response details:
● Name of hospital trust:
● Address of hospital trust:
● Name of laboratory providing histology services:
● Address of laboratory providing histology services:
 
Answer To Question 1:
Please see attached document. FOI Breast Cancer 2020.docx
 
Question Number 2:
Do you perform diagnostic reporting of breast cancers in the house? [Y/N]
● If Y, what types?
 
Answer To Question 2:
Please see question 1.
 
Question Number 3:
What are the steps involved in diagnostic reporting once a tissue sample has been received? Please tick as appropriate.

● Tissue preparation
● Primary diagnosis by pathologist
● Molecular test
● Secondary diagnosis (opinion)
● MDT
● Other - please specify
 
Answer To Question 3:
Please see question 1.
 
Question Number 4:
How many breast cases do you receive per year?
● <100
● 100-500
● 500-1000
● 1000+ (please specify an approximate number)
 
Answer To Question 4:
Please see question 1.
 
Question Number 5:
What % of breast samples received constitute breast cancers?
● <25%
● 25-50%
● 50-75%
● 75-100%
 
Answer To Question 5:
Please see question 1.
 
Question Number 6:
What % of breast samples come from Breast Cancer Screening? What % of breast cancers come from Breast Cancer Screening Program?
● <25%
● 25-50%
● 50-75%
● 75-100%
 
Answer To Question 6:
Please see question 1.
 
Question Number 7:
What are the additional tests performed for characterisation of breast cancers? Select all that apply:
● Estrogen receptor IHC
● Progesterone Receptor IHC
● Her2 Receptor IHC
● Her2 Receptor FISH
● Ki67 IHC
● OncotypeDx
● Others (please specify)
 
Answer To Question 7:
Please see question 1.
 
Question Number 8:
Which of the below tests are routinely performed? For non-routine/conditional tests, please specify the conditions for these tests to be performed.

● Estrogen receptor IHC
● Progesterone Receptor IHC
● Her2 Receptor IHC
● Her2 Receptor FISH
● Ki67 IHC
● Oncotype Dx
● Others (please specify)
 
Answer To Question 8:
Please see question 1.
 
Question Number 9:
What is the cost per patient for the following tests?

● Estrogen receptor IHC
● Progesterone Receptor IHC
● Her2 Receptor IHC
● Her2 Receptor FISH
● Ki67 IHC
● OncotypDx
● Others (please specify)
If cost per patient is not available, please provide whatever cost breakdown is available (total number of patients + total cost of testing OR total cost of all tests per patient OR routine cost of IHC/FISH + number of cases tested etc.). Please specify the type of costs provided.
 
Answer To Question 9:
Please see question 1.
 
Question Number 10:
What is the average turnaround time for following steps? Is there any mandated target for each step? If so, what % of cases exceed the target?
● Preparation of diagnostic biopsy
● Primary Diagnostic Reporting
● IHC testing
● Other molecular testing
NOTE: where numbers for breast malignancies are unavailable, overall numbers will be accepted (please indicate).
 
Answer To Question 10:
Please see question 1.
 
Question Number 11:
What percentage of cases exceed a 7 day turnaround time and 14 days respectively?
 
Answer To Question 11:
Please see question 1.
 
Question Number 12:
Did your histology laboratory use any form of digital/computational
pathology in 2019 [Y/N]
● If [N] to the above question are you planning to introduce digital pathology in the near future (please provide details)?

NOTE: If your histology laboratory does not currently use any form of digital/computational pathology, the remainder of this section can be left blank. Please proceed to Section 4.
 
Answer To Question 12:
Please see question 1.
 
Question Number 13:
What was digital pathology used for in your laboratory during 2019?
● Research
● Training
● Primary diagnosis
● Secondary diagnosis (second opinion)
● Telepathology (Requestor)
● Telepathology (Consultant)
● Preparing cases for review at multi-disciplinary team meetings
● Other (please detail)
 
Answer To Question 13:
Please see question 1.
 
Question Number 14:
Please indicate which of the listed systems were used in your histology
laboratory in 2019. If a software suite is used please indicate the features used from the suite.
● Telepathology
● Whole Slide Imaging
● Image analysis
● Conventional (analogue) light microscopy
● Voice recognition system for reporting
● Digital case requesting (ICE) system
● Digital dissection macro imaging systems
● Voice recognition system for dissection
● Specimen tracking system
● Pathology reporting software
● LIS/LIMS/PACS
● Other (please detail)
 
Answer To Question 14:
Please see question 1.
 
Question Number 15:
If whole slide imaging was used in your laboratory in 2019 please provide
the following details on system configuration.
● Number of scanners (and manufacturer)
● PACS/ Image management systems provider
● Current size of digital slide archive
o Total number of cases
o Number of years
o Estimated retrospective digitization rate (%)
● Number of slides routinely scanned per week
o Of these, how many are on-demand
● Number of slides routinely scanned at 40x
o For diagnostic reporting
o For other purposes
● Other (please detail)
 
Answer To Question 15:
Please see question 1.
 
Question Number 16:
Section 4: Future use of digital/computational pathology (only to be filled if Section 3 does not apply)

Q16: Which of the following reasons best describes why you have not used or increased your use of digital pathology?
● High costs
● Lack of evidence surrounding clinical effectiveness
● Staff training requirements
● Disruption to current workflows
● Lack of existing digital infrastructure
● Other (please specify)
 
Answer To Question 16:
Please see question 1.
Please see attachments:
FOI Breast Cancer 2020.docx
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Salisbury NHS Foundation Trust, Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2021 Salisbury NHS Foundation Trust
Trust Values